T Steuber1, T Maurer2, K Miller3. 1. Martini-Klinik, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, Gebäude Ost 46, 20246, Hamburg, Deutschland. steuber@uke.de. 2. Martini-Klinik, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, Gebäude Ost 46, 20246, Hamburg, Deutschland. 3. Klinik für Urologie, Universitätsklinikum Charite Berlin, Berlin, Deutschland.
Abstract
BACKGROUND: Prostate cancer metastases may occur at diagnosis (de novo) or metachronous after treatment for localized disease. OBJECTIVE: To describe location, prognosis, and individual treatment concepts for metachronous oligometastatic prostate cancer. MATERIALS AND METHODS: Analysis of current treatment guidelines and literature for hormone sensitive, metachronous metastatic prostate cancer. RESULTS: Modern imaging modalities lead to earlier diagnosis of metachronous oligometastatic prostate cancer, which offers the opportunity to develop metastasis-directed treatment concepts. Oligometastatic recurrence may occur in locoregional lymph nodes (N1) or as distant disease (M1). N1 disease is predominantly treated by salvage lymph node dissection or radiation. Distant metastasis may be radiated in order to delay systemic treatment. The combination of androgen deprivation and novel androgen receptor-targeted drugs such as apalutamide or enzalutamide are associated with a significant survival benefit compared to castration alone in bone or visceral oligometastatic metachronous disease. CONCLUSION: Metachronous oligometastatic prostate cancer is heterogeneous with slow progression compared to men with high volume metastasis. Individual treatment concepts may decrease risk of progression and, thus, delay time to medical treatment. Multimodal approaches are currently being evaluated in clinical trials.
BACKGROUND: Prostate cancer metastases may occur at diagnosis (de novo) or metachronous after treatment for localized disease. OBJECTIVE: To describe location, prognosis, and individual treatment concepts for metachronous oligometastatic prostate cancer. MATERIALS AND METHODS: Analysis of current treatment guidelines and literature for hormone sensitive, metachronous metastatic prostate cancer. RESULTS: Modern imaging modalities lead to earlier diagnosis of metachronous oligometastatic prostate cancer, which offers the opportunity to develop metastasis-directed treatment concepts. Oligometastatic recurrence may occur in locoregional lymph nodes (N1) or as distant disease (M1). N1 disease is predominantly treated by salvage lymph node dissection or radiation. Distant metastasis may be radiated in order to delay systemic treatment. The combination of androgen deprivation and novel androgen receptor-targeted drugs such as apalutamide or enzalutamide are associated with a significant survival benefit compared to castration alone in bone or visceral oligometastatic metachronous disease. CONCLUSION: Metachronous oligometastatic prostate cancer is heterogeneous with slow progression compared to men with high volume metastasis. Individual treatment concepts may decrease risk of progression and, thus, delay time to medical treatment. Multimodal approaches are currently being evaluated in clinical trials.
Authors: Matthias Eiber; Ken Herrmann; Jeremie Calais; Boris Hadaschik; Frederik L Giesel; Markus Hartenbach; Thomas Hope; Robert Reiter; Tobias Maurer; Wolfgang A Weber; Wolfgang P Fendler Journal: J Nucl Med Date: 2017-11-09 Impact factor: 10.057
Authors: Patrick Bowden; Andrew W See; Mark Frydenberg; Hodo Haxhimolla; Anthony J Costello; Daniel Moon; Paul Ruljancich; Jeremy Grummet; Alan Crosthwaite; Ganes Pranavan; Justin S Peters; Kevin So; Stella M Gwini; Dean P McKenzie; Skye Nolan; Lloyd M L Smyth; Craig Everitt Journal: Int J Cancer Date: 2019-06-28 Impact factor: 7.396
Authors: Kim N Chi; Simon Chowdhury; Anders Bjartell; Byung Ha Chung; Andrea J Pereira de Santana Gomes; Robert Given; Alvaro Juárez; Axel S Merseburger; Mustafa Özgüroğlu; Hirotsugu Uemura; Dingwei Ye; Sabine Brookman-May; Suneel D Mundle; Sharon A McCarthy; Julie S Larsen; Weili Sun; Katherine B Bevans; Ke Zhang; Nibedita Bandyopadhyay; Neeraj Agarwal Journal: J Clin Oncol Date: 2021-04-29 Impact factor: 44.544
Authors: Matthias Eiber; Markus Kroenke; Alexander Wurzer; Lena Ulbrich; Lena Jooß; Tobias Maurer; Thomas Horn; Kilian Schiller; Thomas Langbein; Gabriel Buschner; Hans-Jürgen Wester; Wolfgang Weber Journal: J Nucl Med Date: 2019-12-13 Impact factor: 10.057
Authors: Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Peter De Porre; Thian Kheoh; Youn C Park; Mary B Todd; Kim N Chi Journal: N Engl J Med Date: 2017-06-04 Impact factor: 91.245
Authors: Carlo A Bravi; Nicola Fossati; Giorgio Gandaglia; Nazareno Suardi; Elio Mazzone; Daniele Robesti; Daniar Osmonov; Klaus-Peter Juenemann; Luca Boeri; R Jeffrey Karnes; Alexander Kretschmer; Alexander Buchner; Christian Stief; Andreas Hiester; Alessandro Nini; Peter Albers; Gaëtan Devos; Steven Joniau; Hendrik Van Poppel; Shahrokh F Shariat; Axel Heidenreich; David Pfister; Derya Tilki; Markus Graefen; Inderbir S Gill; Alexander Mottrie; Pierre I Karakiewicz; Francesco Montorsi; Alberto Briganti Journal: Eur Urol Date: 2020-07-02 Impact factor: 24.267
Authors: N W Clarke; A Ali; F C Ingleby; A Hoyle; C L Amos; G Attard; C D Brawley; J Calvert; S Chowdhury; A Cook; W Cross; D P Dearnaley; H Douis; D Gilbert; S Gillessen; R J Jones; R E Langley; A MacNair; Z Malik; M D Mason; D Matheson; R Millman; C C Parker; A W S Ritchie; H Rush; J M Russell; J Brown; S Beesley; A Birtle; L Capaldi; J Gale; S Gibbs; A Lydon; A Nikapota; A Omlin; J M O'Sullivan; O Parikh; A Protheroe; S Rudman; N N Srihari; M Simms; J S Tanguay; S Tolan; J Wagstaff; J Wallace; J Wylie; A Zarkar; M R Sydes; M K B Parmar; N D James Journal: Ann Oncol Date: 2019-12-01 Impact factor: 32.976
Authors: Charlotte L Deijen; Gerbert L Vrijenhoek; Eva E Schaake; Wouter V Vogel; Luc M F Moonen; Floris J Pos; Henk G van der Poel; Gerben R Borst Journal: Clin Transl Radiat Oncol Date: 2021-06-29